PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMetformin glycinate
Metformin glycinate
/ Metformin, Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Komboglyze, Metformin, Metformin /, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Sitagliptin / Metformin, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin glycinate) is an unknown pharmaceutical. Metformin glycinate was first approved as Glucophage on 1995-03-03. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
actoplus metNew Drug Application2024-06-28
alogliptin and metformin hydrochlorideNDA authorized generic2024-02-12
appforminunapproved drug other2011-08-08
appformin-dunapproved drug other2011-08-08
avandametNew Drug Application2012-08-30
dapagliflozin and metformin hydrochlorideNDA authorized generic2024-12-20
fortametNew Drug Application2010-03-15
glipizide and metformin hydrochlorideANDA2018-12-11
glipizide and metformin hydrochloride glipizide and metformin hydrochlorideANDA2024-12-04
glipizide and metformin hclANDA2024-12-20
Show 40 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM
2026-12-20PED
2026-06-20NPP
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM
2026-12-20PED
2026-06-20M-296
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM
2026-12-20PED
2026-06-20M-295
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM
2026-12-20PED
2026-06-20M-295
ALOGLIPTIN BENZOATE / METFORMIN HYDROCHLORIDE, KAZANO, TAKEDA PHARMS USA
2026-07-27M-300
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK
2024-09-17M-275
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK
2024-06-04PED
2023-12-04M-187
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MSD SUB MERCK
2024-06-04PED
2023-12-04M-187
Patent Expiration
Patent
Expires
Flag
FDA Information
Metformin Hydrochloride, Riomet Er, Sun Pharm
99623362035-05-01DP
Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim
99499982034-06-11U-2290, U-2731
102586372034-04-03U-2290, U-2731
110903232034-04-03U-3192, U-3193
118331662034-04-03U-3776, U-3777
105961202032-03-07DPU-2775, U-2776, U-2790, U-2792
115648862032-03-07DPU-3531
104061722030-06-15DPU-2733
91557052030-05-21DP
85519572029-10-14DPU-2730
94150162029-04-02DP
100223792029-04-02U-2339, U-2732
75794492028-08-01DP
77139382027-04-15DS, DP
88838052025-11-26DP
74079552025-05-02DS, DP
Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim
99499972034-05-17U-3532, U-3533
118132752034-04-03U-3759
106104892030-09-30DP
Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim
95550012033-03-06DPU-1967, U-1968
91738592027-05-04DPU-1503
Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab
96160282030-11-12DP
86859342030-05-26U-1522
79195982029-12-16DP
85016982027-06-20DPU-493
65151172025-10-04DS, DPU-493
Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck
93082042030-10-21DP
94399022030-10-21U-2214
80805802030-07-13DS, DPU-2214
Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms
115768942030-07-06DP
79435822029-02-26DS, DPU-493, U-2441, U-2632
85132022027-12-03DS, DPU-493, U-2441, U-2632
79437882027-07-14DS, DP
82222192025-04-11U-493, U-2441, U-2632
87854032024-07-30DP
Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim
88466952030-06-04U-1503
109738272029-04-02DP
86739272027-05-04U-1503
Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa
89006382029-05-24DP
78076892028-06-27DS, DPU-1337
82885392025-06-24DP
81736632025-03-15U-1338
Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa
93207142029-02-03DP
91016602027-01-22DP
Show 5 more
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2849 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E112————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMetformin glycinate
INNmetformin glycinate
Description
Actoplus Met, Avandamet, Competact, Ebymect, Efficib, Eucreas, Fortamet, Glucovance, Glumetza, Icandra, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Metaglip, Prandimet, Qternmet, Qtrilmet, Ristfor, Segluromet, Synjardy, Trijardy, Velmetia, Vipdomet, Vokanamet, Xigduo, Zituvimet, Zomarist (metformin glycinate) is an unknown pharmaceutical. Metformin glycinate was first approved as Glucophage on 1995-03-03. It has been approved in Europe to treat type 2 diabetes mellitus.
Classification
Unknown
Drug classhypoglycemics (phenformin type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID121369-64-0
RxCUI—
ChEMBL IDCHEMBL2108299
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDYEI21W005Y (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Janumet – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 23,578 documents
View more details
Safety
Black-box Warning
Black-box warning for: Actoplus met, Alogliptin and metformin hydrochloride, Appformin, Appformin-d, Avandamet, Dapagliflozin and metformin hydrochloride, Fortamet, Glumetza, Glyburide and metformin hydrochloride, Glyburide-metformin hydrochloride, Invokamet, Invokamet invokamet xr, Janumet, Jentadueto, Jentadueto xr, Kazano, Kombiglyze, Metformin er 500 mg metformin er 750 mg, Metformin hcl, Metformin hydrochloride, Metformin hydrochloride extended release, Metformin hydrochloride extended-release, Metformin hydrochloride metformin hydrochloride, Metformin hydrochloride oral solution, Pioglitazole and metformin hydrochloride, Pioglitazone and metformin, Pioglitazone hydrochloride and metformin hydrochloride, Saxagliptin and metformin, Saxagliptin and metformin hydrochloride, Segluromet, Sitagliptin and metformin hydrochloride, Synjardy, Synjardy synjardy, Trijardy xr, Xigduo, Zituvimet, Zituvimet xr
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
147,946 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use